SEC Form 10-KT filed by Estrella Immunopharma Inc.
$ESLA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
8-K - Estrella Immunopharma, Inc. (0001844417) (Filer)
8-K - Estrella Immunopharma, Inc. (0001844417) (Filer)
10-Q - Estrella Immunopharma, Inc. (0001844417) (Filer)
Estrella Immunopharma, Inc. (NASDAQ:ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, announces that, as previously disclosed in its Current Report on Form 8-K filed on September 29, 2025, the Company has regained compliance with the listing requirements of The Nasdaq Stock Market LLC ("Nasdaq"). This confirmation follows the Company's successful efforts to improve its balance sheet, including raising new capital to continue development of its therapeutic candidates. Specifically, on September 23, 2025, the Company received two letters from the Listing Qualifi
Estrella Immunopharma, Inc. (NASDAQ:ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). The new site, Baylor Research Institute d/b/a Baylor Scott & White Research Institute in Dallas, Texas, is now open for patient enrollment. "Partnering with Baylor Research Institute, a nationally recognized medical institution, re
Estrella Immunopharma, Inc. (NASDAQ:ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that on May 30, 2025, it entered into a securities purchase agreement (the "Purchase Agreement") for a private investment in public equity ("PIPE") financing that is expected to result in approximately $3.35 million in gross proceeds. Pursuant to the terms of the securities purchase agreement, at the closing of the PIPE financing, Estrella will issue an aggregate of 2,333,334 shares of its common stock at a price of $1.50 per share. The last reported sale pric
3 - Estrella Immunopharma, Inc. (0001844417) (Issuer)
4 - Estrella Immunopharma, Inc. (0001844417) (Issuer)
4 - Estrella Immunopharma, Inc. (0001844417) (Issuer)
Estrella Immunopharma, Inc. (NASDAQ:ESLA, ESLAW))) ("Estrella", "Estrella Immunopharma", or the "Company"), a clinical stage biopharmaceutical company focused on developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancers and autoimmune diseases, today announced the appointment of Hong Zhang as Chairperson and a member of its Board of Directors. This appointment comes shortly after the Company dosed the first patient in its Phase I/II clinical trial (STARLIGHT-1) for EB103, an autologous T-cell therapy for adult patients with relapsed or refractory (R/R) B-cell Non-Hodgkin's Lymphoma (NHL). Ms. Zhang's appointment increases the size of Estrella's Board from five to six dire